To offer a better treatment option for arthritis patients, researchers have found that a small protein appears to protect against bone loss that often accompanies arthritis.
The researchers are now interested to see if Glucocorticoid-induced leucine zipper (GILZ), which is produced naturally in the body, can prevent arthritis from developing in the face of inflammation.
Arthritis as well as ageing prompt the body to make more fat than bone.
"We have early evidence that GILZ might one day offer a better treatment option for arthritis patients than widely used synthetic glucocorticoids, which actually increase bone loss," said Xingming Shi, a bone biologist at the Georgia Regents University in the US.
Directly over-expressing the protein appears to better target sources of bone loss and inflammation and avoid the serious side effects associated with glucocorticoid treatment.
For this study, the focus was tumour necrosis factor alpha, a pro-inflammatory cytokine (small protein) that helps regulate immune cells and is a major player in arthritis.
To look specifically at the impact on bone loss, the researchers crossed mice bred to over-express tumour necrosis factor alpha throughout the body with mice that over-expressed GILZ in stem cells.
"While the mice that over-expressed only tumour necrosis factor alpha quickly developed arthritis along with significant bone and weight loss, those that also over-expressed GILZ had significantly less bone loss," Shi said.
Their findings are scheduled to be presented at The American Society for Bone and Mineral Research 2014 Annual Meeting during Sep 12-15 at Houston in the US.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
